EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Community-Acquired Bacterial Pneumonia – a Challenging Diagnosis in Clinical Trials
Editorial Archive

Community-Acquired Bacterial Pneumonia – a Challenging Diagnosis in Clinical Trials

Community-acquired bacterial pneumonia is a common and important disease which is associated with significant morbidity and mortality worldwide. Various pathogens cau...
Continue Reading →
Drugs’ Marketing Authorization and Clinical Trials Regulations in Ukraine
Editorial Archive

Drugs’ Marketing Authorization and Clinical Trials Regulations in Ukraine

Dr. Sergiy Pakharyna, at Synergy Group Ukraine, Dr. Yuri Afonchikov of Synergy Research Group, analyses the marketing authorization and clinical trials regulations in...
Continue Reading →
Romania`s Regulatory Framework for Clinical Trials
Editorial Archive

Romania`s Regulatory Framework for Clinical Trials

Romania is located in Southeastern Central Europe, north of the Balkan Peninsula and on the western shore of the Black Sea. With a population of 20.1 million, it is t...
Continue Reading →
Operational Challenges Associated with Biosimilar Drug Development
Editorial Archive

Operational Challenges Associated with Biosimilar Drug Development

This article examines the current operational landscape of biosimilar clinical drug development and identifies opportunities to decrease the risks associated with inc...
Continue Reading →
Improving the quality and accessibility of clinical data collection through patient engagement
Editorial Archive

Improving the quality and accessibility of clinical data collection through patient engagement

It is widely recognised that putting the patient at the centre of a trial's design can significantly improve the quality and accessibility of data collection. To do t...
Continue Reading →
Understanding Stroke from the Perspective of the Large Arteries
Editorial Archive

Understanding Stroke from the Perspective of the Large Arteries

Stroke, as it has recently been redefined, is any objective evidence of permanent brain, spinal, or retinal cell death due to a vascular cause. In general, strokes ar...
Continue Reading →
Scandinavia/Nordic: Are they just ice and snow?
Editorial Archive

Scandinavia/Nordic: Are they just ice and snow?

Denmark leads the way in clinical trials with more than 4,700 so far. Sweden has run over 3,200 trials. These numbers reflect the progressive biotech industry in the ...
Continue Reading →
Phase 1 Clinical Trials in an Era of Increasing Oncologic Success
Editorial Archive

Phase 1 Clinical Trials in an Era of Increasing Oncologic Success

Between 2010 and 2014, 37 new molecular entities were approved by the FDA for the treatment of cancer; and between 1995 and 1999, only 20 such agents were approved. M...
Continue Reading →
CSF Biomarkers of disease Modification in Alzheimer’s Disease
Editorial Archive

CSF Biomarkers of disease Modification in Alzheimer’s Disease

The three major brain hallmarks of Alzheimer’s disease (AD) are extracellular amyloid plaques, axonal degeneration and intraneuronal neurofibrillary tangles, which ca...
Continue Reading →
FDA Makes First Move on biosimilars in the US
Editorial Archive

FDA Makes First Move on biosimilars in the US

Regina Ballinger and Deborah Komlos from Thomson Reuters are submitting an interesting editorial titled FDA Makes First Move on Biosimilars in the US, and they give u...
Continue Reading →
Catalyst: 12th January 2026
Quotient